相关实验视频
Updated: Jun 20, 2025

09:42
A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
Published on: June 4, 2021
2.7K
蒂罗菲班通过减少炎症反应来调解急性缺血性中风的神经保护作用
Wei Liu1, Xu Man2, Yongbin Wang1
1Department of Emergency Medicine, The Affiliated Hospital of Qingdao University, College of Medicine, Qingdao University, Qingdao 266003, China.
Neuroscience
|July 18, 2024
概括
蒂罗菲班通过减少神经炎症来减少脑损伤,并改善急性缺血性中风 (AIS) 的功能. 这项研究表明,蒂罗菲班调节微质,降低炎症类细胞因子,提供神经保护.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 神经炎症是急性缺血性中风 (AIS) 进展和神经元死亡的关键因素.
- 已知tirofiban通过抑制血小板聚合来改善AIS的功能恢复,但其在神经炎症中的作用尚不清楚.
研究的目的:
- 在AIS的小鼠模型中调查tirofiban对神经炎症的影响和机制.
- 为了确定蒂罗菲班是否通过调节炎症反应来提供神经保护.
主要方法:
- 使用光化学技术创建了一个AIS鼠标模型.
- 通过使用mNSS和TTC染色来评估神经功能和心脏病发作大小.
- 分析了氧化应激,亡,基因表达 (DNA微阵列),蛋白质水平 (蛋白质微阵列) 和微质表型.
主要成果:
- 在AIS小鼠中,蒂罗菲班显著降低了脑梗塞的体积,并改善了神经功能.
- 蒂罗菲班减轻了缺血半阴影中的氧化损伤和亡.
- 蒂罗菲班降低了炎症通路的调节,降低了关键的炎症细胞因子 (IL-1,IL-6,TNF-α),并调节了微质状态和表型.
结论:
- 蒂罗菲班通过减少神经炎症,在AIS中发挥神经保护作用.
- 该药物通过调节微质激活和减少促炎因素的释放来实现这一目标.
- 这些发现突出了提罗非班作为一种潜在的治疗剂,针对AIS中的神经炎症.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
510
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
510
Anticoagulant Drugs: Low-Molecular-Weight Heparins
668
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
668
Clot Retraction and Fibrinolysis
5.4K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.4K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Introduction to Hemostasis
7.1K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
7.1K

